14Aug

OGT launches enhanced SureSeq™ Interpret NGS analysis software

ogt-logo

Oxford, UK – 07 August 2018. Oxford Gene Technology (OGT), The Molecular Genetics Company, has announced the launch of the eagerly-anticipated update to its SureSeq™ Interpret software, included with purchases of SureSeq NGS panels. Designed to help researchers effortlessly translate cumbersome NGS data into meaningful results, OGT has leveraged its renowned bioinformatics expertise to develop the new, significantly enhanced software in response to customer needs. The company, well known for its popular and highly-regarded CytoSure™ Interpret microarray analysis software, will with SureSeq Interpret, deliver an easy-to-use, accurate and precise NGS analysis solution that offers extensive flexibility to meet individual laboratory requirements.

SureSeq Interpret has been designed to be used with SureSeq NGS panels, facilitating analysis and visualisation of a wide range of mutation types and structural variants. Working in tandem with OGT’s expert panel design and hybridisation-based approach that delivers unparalleled coverage uniformity in sequencing reactions, SureSeq Interpret is integral to enabling low-frequency variants to be detected confidently and consistently.

Powerful and easy-to-use, the software rapidly processes sequencing data and delivers accurate mutation calling with 100% sensitivity and 99.9% specificity at >1% variant allele frequency (VAF)*. SureSeq Interpret reliably identifies single nucleotide variants (SNVs) and Indels as well as structural variants such as copy number variants (CNVs) and internal tandem duplications (ITDs) - meaning that researchers can rely on the software for all their mutation detection and analysis needs. Beta triallist Joshua Landreth, Molecular Laboratory Supervisor at Genetic Associates Inc, observed “The software provided quick and reliable alignment and variant analysis to interpret results from our core MPN sequencing.”

A comprehensive filtering framework enables analysis workflows to be standardised and allows variant filtering to be overlaid to meet analytical criteria. Extensive customisation options enable researchers to easily tailor variant and batch reports and database links to meet the exact needs of the laboratory. Flexibility and ease of use is integral to the design, and features accessibility via a stand-alone computer, laboratory server or other web-enabled devices. Finally, security and control have also been well-provisioned for, with a built-in ability to log and track user activity and standardise analysis protocols via multiple access permission levels.

Dave Cook, Senior Product Manager at OGT, commented, “We are delighted to be offering these enhanced capabilities for our SureSeq Interpret software to complement our world-class custom bait design, panel development and library preparation. We realised there was a gap for freely-available, accurate and precise NGS analysis software that also offers a high degree of flexibility in terms of analysis, filtering options, and security controls and SureSeq Interpret has been developed to address that need. OGT is well known for our highly-rated CytoSure Interpret microarray analysis software, and SureSeq Interpret follows on from that. We want to enable researchers to focus on their research, rather than struggling to sift through data”

For more information please visit www.ogt.com.

 

Related

European Reference Laboratory for Glycohemoglobin study reaffirms EKF’s Quo-Test® meets HbA1c performance criteria

Cardiff, UK – 16th February 2017 – EKF Diagnostics, the global in vitro diagnostics company, annou...

Read More >

BBI Solutions & Dr C. Sturgeon consider International Standards for Cancer Biomarkers

Dr Catharine Sturgeon will be presenting her case for an international effort to align manufacturer’...

Read More >

QIAGEN announces FDA approval of PartoSure

Germantown, Maryland, and Hilden, Germany, April 20, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prim...

Read More >

Biofortuna expands its immunoassay development and manufacturing services

Biofortuna is expanding its IVD service portfolio to provide a greater focus on immunoassay design, ...

Read More >

RPS Diagnostics partners with Atomo Diagnostics to develop next generation Febridx blood tests for Antibiotic Stewardship in the Outpatient setting

Sarasota, Florida and Sydney, Australia (February 20, 2018) – United States biotechnology company, ...

Read More >

First global install of HORIBA Medical’s new track-based haematology platform achieves Quality Accreditation

New HELO fully automated high throughput system at Torbay reduces time taken for routine haematology...

Read More >